The epidermal growth factor receptor (EGFR) is a cellular transmembrane receptor with
tyrosine kinase enzymatic activity which plays a key role in human cancer. EGFR-dependent …

The epidermal growth factor receptor (EGFR) is a promising target for cancer therapy and a
number of EGFR-targeted agents have been developed. Those most advanced in …

Twenty years after the epidermal growth factor receptor (EGFR) was identified as a potential
anticancer target, the EGFR inhibitor gefitinib (Iressa; AstraZeneca) has been approved for …

The epidermal growth factor receptor (EGFR) plays an essential role in normal cell growth
and differentiation and in the survival of healthy and cancerous cells. EGFR expression is a …

Gefitinib (ZD1839, Iressa®), a selective drug inhibitor of the epidermal growth factor receptor
(EGFR) tyrosine kinase (TK), was recently approved for the treatment of patients with …

Epidermal growth factor receptor (EGFR) actively involves in modulation of various cancer
progression related mechanisms including angiogenesis, differentiation and migration …

The epidermal growth factor receptor (EGFR) is an important mediator of normal cellular
processes such as growth, survival, differentiation and morphogenesis. Disturbances in the …

The epidermal growth factor receptor (EGFR) is overexpressed in as many as 77% of
colorectal cancer (CRC) cases. The EGFR is known to be involved in carcinogenetic …

Over the past few years, epidermal growth factor receptor has emerged as one of the most
important targets in tumorgenesis and several drugs targeting signal transduction pathways …

A key signature of targeted cancer therapy is selectivity. This selectivity depends on
identification of a target that is tightly associated with the malignant phenotype. Inhibition of …